CAR T-cell therapy with obecabtagene autoleucel (obe-cel) represents a promising treatment route for adult patients with B-cell acute lymphoblastic leukemia (B-ALL), a population with historically limited treatment options, according to Paul J .Shaughnessy, MD. The phase 1/2 FELIX study (NCT04404660) is evaluating the safety and efficacy of obe-cel, a CD19-targeted agent, in adult patients with […]